LivaNova Reports Strong 2025 Growth but Faces Environmental Liability Hit
Event summary
- LivaNova reported $1.39 billion in full-year 2025 revenue, up 10.7% year-over-year.
- Fourth-quarter 2025 revenue increased 12.1% to $360.9 million.
- Full-year 2025 GAAP diluted loss per share was $4.45 due to a $365.6 million SNIA environmental liability expense.
- LivaNova received FDA approval for its cloud-based digital health platform and increased Medicare reimbursement for VNS Therapy.
The big picture
LivaNova's strong revenue growth in 2025 was driven by its Cardiopulmonary and Epilepsy businesses, but the company faces challenges from environmental liabilities. The increased Medicare reimbursement for VNS Therapy and FDA approval of its digital health platform position LivaNova to capitalize on high-growth, high-margin opportunities in obstructive sleep apnea (OSA). The company's strategic focus on innovation and disciplined capital allocation will be key to sustaining its performance in 2026.
What we're watching
- Reimbursement Impact
- How the increased Medicare reimbursement for VNS Therapy will affect LivaNova's revenue growth in 2026.
- Environmental Liability
- Whether LivaNova can sustain its financial performance amid significant environmental liability expenses.
- Digital Health Expansion
- The pace at which LivaNova's cloud-based digital health platform will drive patient engagement and outcomes.